Q2 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Key Points
- Swedish Orphan Biovitrum AB (BIOVF) reported a 22% revenue growth at constant currency, reaching 6.2 billion in Q2 2025.
- The company's strategic growth portfolio now accounts for 55% of total revenues, with a remarkable growth of 65%.
- Significant R&D milestones were achieved, including FDA approval for Gamifant in HLH MAS and disease, and strong 52-week data for Aspaveli in nephrology indications.
- The hemophilia franchise demonstrated robust growth, with a 27% increase, driven by products like Alvoct and Elocta.
- The company successfully renegotiated a royalty agreement with Apellis, reducing ex-US royalty obligations by 90% until certain caps are reached.
- Wanzhou experienced a 4% decline in demand, attributed to gross-to-net adjustments and external healthcare reforms.
- The company faces competitive pressure in the PNH space, particularly in Europe, affecting growth potential.
- Despite strong growth, the company maintained a cautious outlook on guidance due to uncertainties in the US healthcare landscape and competition.
- Restructuring charges of 208 million were recorded, reflecting a strategic decision to reallocate resources, impacting short-term financials.
- The CTI acquisition faced challenges, with some unforeseen competitive dynamics affecting expected outcomes.
()-
Hello everybody. This is Guido Ercas, CEO of Sobi.
We are delighted to welcome you to the 2nd quarter 2025 conference call for investors and analysts. We posted this presentation to Sobi.com earlier.
Forward-looking statement as per usual, please take note of this.
And with this, let's go right into the next slide today we plan to cover key aspects of our Q2 report. I'm joined by Henrik Stenquist, our CFO, and Lidia Abaran, head of R&D and Chief Medical Officer. We plan to review the presentation first.
And then have a Q&A until until around 3 p.m. CT.
For those on the phone, please join the queue and for questions, as mentioned, please press 1.
And we ask you to only really request only to ask one maximum 2 questions at a time. Let's go to slide number 4.
The 2nd quarter when you elevate yourself was really for us about, strong economics, drive important pipeline milestones and create economic preconditions to support our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
